{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T08:25:01Z","timestamp":1793348701836,"version":"4.5.0"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","license":[{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["painjournalonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1016\/j.pain.2014.03.018","type":"journal-article","created":{"date-parts":[[2014,3,28]],"date-time":"2014-03-28T21:17:42Z","timestamp":1396041462000},"page":"1245-1252","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":104,"title":["Fasinumab (REGN475), an antibody against nerve growth factor for the treatment of pain: Results from a double-blind, placebo-controlled exploratory study in osteoarthritis of the knee"],"prefix":"10.1097","volume":"155","author":[{"given":"Paul J.","family":"Tiseo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan J.","family":"Kivitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John E.","family":"Ervin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haobo","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott J.","family":"Mellis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-13-20210126","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1002\/art.1780290816","article-title":"Development of criteria for the classification and reporting of osteoarthritis: classification of osteoarthritis of the knee.","volume":"29","author":"Altman","year":"1986","journal-title":"Arthritis Rheum"},{"key":"R2-13-20210126","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.joca.2007.02.006","article-title":"Efficacy and safety of opioids for osteoarthritis: a meta-analysis of randomized controlled trials.","volume":"15","author":"Avouac","year":"2007","journal-title":"Osteoarthritis Cartilage"},{"key":"R3-13-20210126","doi-asserted-by":"crossref","first-page":"R82","DOI":"10.1186\/ar2716","article-title":"Nerve growth factor and receptor expression in rheumatoid arthritis and spondyloarthritis.","volume":"11","author":"Barthel","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"R4-13-20210126","first-page":"1833","article-title":"Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee.","volume":"15","author":"Bellamy","year":"1988","journal-title":"J Rheumatol"},{"key":"R5-13-20210126","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1172\/JCI43195","article-title":"The discovery and development of analgesics: new mechanisms, new modalities.","volume":"120","author":"Burgess","year":"2010","journal-title":"J Clin Invest"},{"key":"R6-13-20210126","first-page":"543","article-title":"Tramadol for osteoarthritis: a systematic review and meta-analysis.","volume":"34","author":"Cepeda","year":"2007","journal-title":"J Rheumatol"},{"key":"R7-13-20210126","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1042\/CS20050163","article-title":"Neurotrophin signaling in health and disease.","volume":"110","author":"Chao","year":"2006","journal-title":"Clin Sci"},{"key":"R8-13-20210126","first-page":"6","article-title":"The increasing impact of arthritis on public health.","volume":"60","author":"Elders","year":"2000","journal-title":"J Rheumatol Suppl"},{"key":"R9-13-20210126","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/j.1530-7085.2003.03034.x","article-title":"The numeric rating scale for clinical pain measurement: a ratio measure?","volume":"3","author":"Hartrick","year":"2003","journal-title":"Pain Pract"},{"key":"R10-13-20210126","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jmpt.2003.11.003","article-title":"Assessing the clinical significance of change scores recorded on subjective outcome measures.","volume":"27","author":"Hurst","year":"2004","journal-title":"J Manipulative Physiol Ther"},{"key":"R11-13-20210126","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1093\/rheumatology\/41.12.1413","article-title":"Lo Bianco G, Lapadula G. Increased expression of nerve growth factor (NGF) and high affinity NGF receptor (p140 TrkA) in human osteoarthritic chondrocytes.","volume":"41","author":"Iannone","year":"2002","journal-title":"Rheumatology"},{"key":"R13-13-20210126","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1056\/NEJMoa0901510","article-title":"Tanezumab for the treatment of pain from osteoarthritis of the knee.","volume":"363","author":"Lane","year":"2010","journal-title":"N Engl J Med"},{"key":"R14-13-20210126","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1097\/01.ajp.0000146215.86038.38","article-title":"Treatment of persistent pain associated with osteoarthritis with controlled-release oxycodone tablets in a randomized controlled clinical trial.","volume":"21","author":"Markenson","year":"2005","journal-title":"Clin J Pain"},{"key":"R15-13-20210126","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.pain.2010.03.002","article-title":"Treatment of murine osteoarthritis with TrkAd5 reveals a pivotal role for nerve growth factor in non-inflammatory joint pain.","volume":"149","author":"McNamee","year":"2010","journal-title":"PAIN"},{"key":"R16-13-20210126","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1146\/annurev.neuro.29.051605.112929","article-title":"Neurotrophins: mediators and modulators of pain.","volume":"29","author":"Pezet","year":"2006","journal-title":"Ann Rev Neurosci"},{"key":"R17-13-20210126","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1002\/1529-0131(200009)43:9<1905::AID-ANR1>3.0.CO;2-P","article-title":"Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines.","volume":"43","year":"2000","journal-title":"Arthritis Rheum"},{"key":"R18-13-20210126","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1136\/ard.2004.032599","article-title":"Involvement of neurotrophins and their receptors in spondyloarthritis synovitis: relation to inflammation and response to treatment.","volume":"64","author":"Rihl","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"R19-13-20210126","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0304-3959(01)00371-2","article-title":"What is a clinically meaningful reduction in pain?","volume":"94","author":"Rowbotham","year":"2001","journal-title":"PAIN"},{"key":"R20-13-20210126","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ejpain.2003.09.004","article-title":"Minimal clinically important changes in chronic musculoskeletal pain intensity measured on a numerical rating scale.","volume":"8","author":"Salaffi","year":"2004","journal-title":"Eur J Pain"},{"key":"R21-13-20210126","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.semarthrit.2009.03.002","article-title":"Nerve growth factor in rheumatic diseases.","volume":"40","author":"Seidel","year":"2010","journal-title":"Semin Arthritis Rheum"},{"key":"R22-13-20210126","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1385\/MN:24:1-3:183","article-title":"Nerve growth factor: a neurokine orchestrating neuroimmune-endocrine functions.","volume":"24","author":"Skaper","year":"2001","journal-title":"Mol Neurobiol"},{"key":"R23-13-20210126","doi-asserted-by":"crossref","first-page":"c7086","DOI":"10.1136\/bmj.c7086","article-title":"Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis.","volume":"342","author":"Trelle","year":"2011","journal-title":"BMJ"},{"key":"R24-13-20210126","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1093\/rheumatology\/keq188","article-title":"Angiogenesis and nerve growth factor at the osteochondral junction in rheumatoid arthritis and osteoarthritis.","volume":"49","author":"Walsh","year":"2010","journal-title":"Rheumatology"},{"key":"R25-13-20210126","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/00005650-199603000-00003","article-title":"A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity.","volume":"34","author":"Ware","year":"1996","journal-title":"Med Care"},{"key":"R26-13-20210126","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2165\/0063030-200822060-00002","article-title":"Targeting nerve growth factor in pain: what is the therapeutic potential?","volume":"22","author":"Watson","year":"2008","journal-title":"BioDrugs"},{"key":"R27-13-20210126","first-page":"646","article-title":"Burden of major musculoskeletal conditions.","volume":"81","author":"Woolf","year":"2003","journal-title":"Bull World Health Organ"},{"key":"R28-13-20210126","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1101\/SQB.1990.055.01.038","article-title":"Neurotrophic factors, their receptors, and the signal transduction pathways they activate.","volume":"55","author":"Yancopoulos","year":"1990","journal-title":"Cold Spring Harb Symp Quant Biol"}],"container-title":["Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1016\/j.pain.2014.03.018","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,16]],"date-time":"2021-06-16T00:49:15Z","timestamp":1623804555000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006396-201407000-00013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":27,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1016\/j.pain.2014.03.018","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718333590.793493027","asserted-by":"object"}]},"ISSN":["0304-3959"],"issn-type":[{"value":"0304-3959","type":"print"}],"subject":[],"published":{"date-parts":[[2014,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fasinumab (REGN475), an antibody against nerve growth factor for the treatment of pain: Results from a double-blind, placebo-controlled exploratory study in osteoarthritis of the knee","name":"articletitle","label":"Article Title"},{"value":"PAIN\u00ae","name":"journaltitle","label":"Journal Title"},{"value":"http:\/\/dx.doi.org\/10.1016\/j.pain.2014.03.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}